AI GxP validation for regulated life sciences
Regulatory

AI Is Now "SI" in US Federal Language: What It Changes for GxP

The White House has directed federal agencies to say Super Intelligence instead of artificial intelligence. What the order actually does, what it explicitly does not touch, and what regulated companies should do about it, which is less than you might think.

Cybroscape Technologies6 min read

Key takeaway

The White House has directed federal agencies to say Super Intelligence instead of artificial intelligence. What the order actually does, what it explicitly does not touch, and what regulated companies should do about it, which is less than you might think.

On 29 September 2026 the White House issued an executive order titled Inaugurating the Era of Super Intelligence. It directs federal departments and agencies to use "Super Intelligence" and "SI" in place of "artificial intelligence" and "AI" in official correspondence, public communications, policy documents and other non-statutory materials.

If you run validation or quality in a regulated company, the useful question is narrow: does anything you are responsible for change? Almost certainly not. Here is what the order says, what it deliberately does not touch, and the small number of practical consequences.

Written 30 September 2026, one day after signing. A federal definition of SI has been commissioned but not yet published, so treat this as a developing picture.

What the order actually does

  • It changes vocabulary inside the executive branch. Agencies are to use "Super Intelligence" and "SI" in correspondence, public communications, websites, reports and policy documents, to the maximum extent permitted by law.
  • It keeps the meaning identical. This is the part most coverage skipped. Section 3(a) defines SI as the technologies and systems already encompassed by "artificial intelligence" as defined in 15 U.S.C. §9401(3). Same scope, new label.
  • It does not rewrite the past. Section 2(b) states that nothing in the relevant section requires altering previously issued regulations, Presidential actions, contracts, grants or historical documents.
  • It commissions a definition. The Assistant to the President for Science and Technology is to propose a federal definition of SI and identify any further executive action needed.

A separate industry accord was signed the same day by a group of technology chief executives. It is voluntary — the President described it as "morally binding" rather than legally enforceable — and commits signatories to internal controls and multiple layers of audits and reviews. We look at that separately in the White House SI accord.

What it does not do

An executive order of this kind cannot amend statute or regulation, and this one explicitly does not try to. So:

  • 21 CFR Part 11 is unchanged, word for word. So are 21 CFR 210/211 and Part 820.
  • EU GMP is entirely outside its reach — Annex 11, the draft Annex 22, the EU AI Act and MHRA guidance all still say artificial intelligence. See US says SI, Europe says AI.
  • GAMP 5 and ISPE guidance are unaffected. They are industry documents, not federal ones.
  • Your validation obligations are identical. Nothing about intended use, risk assessment, testing, human oversight or change control moves because a word changed. See what has not changed.

As of 30 September 2026 the FDA had not published guidance using the new terminology. Existing FDA documents on AI in drug and device contexts still read "artificial intelligence", and the order does not require them to be reissued.

Where it will actually reach you

Three places, over time, and none of them urgent:

  • New FDA communications. Future guidance, web pages and correspondence may use SI. When they do, read them as meaning exactly what AI meant — the order says so explicitly.
  • Inspection conversation. An investigator may use either word. Neither changes what they are entitled to see.
  • Vendor marketing. This is the fastest-moving one, and the least useful. Expect "SI-powered" on slides within the week — covered in SI washing.

What you should not do is launch a documentation project. A find-and-replace across your SOPs creates a change-control burden, a training obligation and a version history full of cosmetic revisions, in exchange for nothing. See do you need to rename AI in your SOPs.

The sensible response

Add a single line to your AI governance or validation procedure noting that US federal materials may use "Super Intelligence (SI)" for what the document calls artificial intelligence, and that the terms are equivalent for the purposes of that procedure. One sentence, one controlled change, no retraining.

Then carry on. The work that makes an AI system defensible in a regulated environment is unchanged: a written intended use, risk proportionate to consequence, honest test data, a qualified person accountable for the output, and monitoring after go-live. That is the subject of GxP AI validation, and none of it turns on what the technology is called this month.

Primary source: the White House fact sheet on the order. Wider context in GxP AI.

Where to go next

Explore Cybroscape GxP Copilot for AI-native validation, Cybroscape TraceDraft for source-traceable clinical documentation, or book a demo to see either on your own data.

Part of our guide to GxP AI — the regulatory framework, validation expectations and platform landscape.

US federal writingSuper Intelligence (SI)The term federal agencies now use
What does not change
  • Intended use defined and bounded
  • Validated before GxP use
  • Data integrity (ALCOA+)
  • A person decides what matters
  • Changes go through change control
EU GMP · Annex 22 · EU AI Act · MHRAArtificial intelligence (AI)The term in EU and UK rules
One quality systemTwo vocabularies, one set of controls
The US federal rename changes the word, not the obligations. EU GMP, the draft Annex 22, the EU AI Act and MHRA still say artificial intelligence, and the validation work is the same under either name.
See it on your own systemBring a URS or a system. We run GxP Copilot against it live on the call.
ai renamed super intelligencegxp super intelligencesi executive order pharmasuper intelligence gxpai to si rename regulated
FAQ

Frequently Asked Questions

Prefer to talk first? Chat with us on WhatsApp or book a call with an expert.

Did the US government actually rename AI to Super Intelligence?

Yes. On 29 September 2026 an executive order titled 'Inaugurating the Era of Super Intelligence' directed federal departments and agencies to use 'Super Intelligence' and 'SI' instead of 'artificial intelligence' and 'AI' in official correspondence, public communications, policy documents and other non-statutory materials, to the maximum extent permitted by law.

Does the SI rename change any regulation?

No. The order covers non-statutory materials within the executive branch, and Section 2(b) states that nothing requires altering previously issued regulations, Presidential actions, contracts, grants or historical documents. 21 CFR Part 11, 210/211 and Part 820 are unchanged, as is all EU and UK guidance.

Is Super Intelligence a different technology from AI?

No. Section 3(a) of the order defines SI as the technologies and systems already encompassed by 'artificial intelligence' as defined in 15 U.S.C. 9401(3). Same scope, different label. A federal definition has been commissioned but not yet published.

Do we need to change our SOPs because of the rename?

No. The order tells federal agencies what words to use in their own materials; it says nothing about private quality systems. A find-and-replace would create change controls, retraining and cosmetic version history for no benefit. One sentence in your AI policy noting the terms are equivalent is enough.

Has the FDA started using SI?

As of 30 September 2026, FDA had published no guidance using the new terminology, and its existing AI documents still read 'artificial intelligence'. The order does not require them to be reissued. Expect the term to appear in new communications over time.

Keep reading

All articles
RegulatoryAfter the SI Rename: Everything About AI Validation That Has Not ChangedPart 11, Annex 11, the draft Annex 22, GAMP 5 and every validation obligation you had last week are untouched by a terminology order. A clear list of what still applies, and the one thing that genuinely might shift. · 5 min readRegulatoryStructured CMC data: managing the dossier as data, not documentsStructured CMC data manages specifications, processes and registrations as linked data instead of copies in documents, so you can see where any fact is registered and what a change affects. · 3 min readRegulatoryWhat Is Super Intelligence (SI)? A Plain Definition for Regulated TeamsSuper Intelligence is now the US federal term for what everyone else still calls AI, and the order defines it as exactly that. What SI means, what it does not mean, and why the everyday sense of the word is not the legal one. · 5 min readRegulatoryAI for regulatory intelligence: let it read, keep people decidingAI is good at monitoring regulatory publications, summarising and sorting them. Deciding what a change means for your products stays with people, and every summary should link to the source passage. · 3 min readRegulatoryAnnex 22 is being rewritten to allow generative AI: what EMA's workshop report saysEMA/156789/2026 records that the drafting group has discussed dropping the generative-AI exclusion in favour of a risk-based control strategy. What changed, what did not, and what to do now. · 10 min readRegulatoryCMC in Pharma: What Chemistry, Manufacturing, and Controls Means for Validation TeamsCMC is where drug development meets manufacturing reality. Here is what validation and quality teams need to understand about CMC requirements, and where validation fits in the CMC lifecycle. · 6 min readRegulatoryICH Q12 in practice: why uptake is slow and where it pays offICH Q12 lets companies agree established conditions with regulators and manage other changes in their own quality system. It pays off most for long-lived products with frequent changes, but needs strong, structured process data. · 3 min readRegulatoryICH Q9(R1): the four changes inspectors now use to challenge risk assessmentsICH Q9(R1), revised in 2023, targets four habits: subjective risk scores, the wrong level of formality, risk assessments that change no decisions, and ignoring product availability. · 3 min read

Bring a system. We'll show you the package.

Book a demo, or ask a validation lead a quick question on WhatsApp.

  • We reply within one business day
  • We run your URS live on the call
  • You get a clear plan for your system
Chat on WhatsApp

Book a demo

Four fields. The right specialist replies within one business day.

Your details stay private. We never share them.